Navigation Links
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
Date:5/4/2009

.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), rheumatoid arthritis, multiple sclerosis, psoriasis, and dermatology. The company is also aiming to expand its development pipeline though licensing-in in the areas mentioned plus some others including gastrointestinal and neurology.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 affiliates (Austria, Belgium, France, Germany, Italy, Mexico, Poland, Portugal, Spain, Switzerland, and the UK-Ireland). For further information please visit the website at: www.almirall.com.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. Linaclotide, the company's first in class compound, is being evaluated in a comprehensive Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia, Inc. (formerly Microbia Precision Engineering), a majority-owned subsidiary of Ironwood, is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Ironwood has raised $281 million in private equity financing and is located in Cambridge, Massachusetts.

    Contact:
    Susan Brady
    Corporate Communications
    617.621.8304
    sbrady@ironwoodpharma.com


'/>"/>
SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
5. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ZURICH, July 16 An innovative ... fibrosis patients has received a second,orphan drug designation ... designation was,granted. The recent designation relates to Burkholderia ... fibrosis patients. For Axentis,Pharma AG of Zurich, Switzerland, ...
... , , , ... are a source of worry for many who fear Alzheimer,s ... July 16 issue of the New England Journal of Medicine suggests that ... to have memory declines in their mid-50s, far earlier than previously thought. ...
Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7
(Date:8/21/2014)... HOUSTON (Aug. 21, 2014) An international scientific ... clues about genetic alterations that may contribute to a ... only into this rare cancer but other types as ... Institutes of Health,s Cancer Genome Atlas initiative , ... published the results today in the journal Cancer ...
(Date:8/21/2014)... 21, 2014Popular fiction that normalizes and glamorizes violence against ... be associated with a greater risk of potentially harmful ... new study are presented in the article " Fiction ... in Adolescent and Young Adult Females ," published in ... from Mary Ann Liebert, Inc., publishers . The ...
(Date:8/21/2014)... N.C. August, 21, 2014 Young girls with ... organs may be at increased risk of developing urinary ... Forest Baptist Medical Center. The treatment may be as ... as bubble baths and swimming pools. , "Vulvitis is ... ages," said senior author Steve J. Hodges, M.D., associate ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 The ... patient survey tool called RateMyHospital®, which captures real-time patient ... improve each patient’s care. The tool, now available to ... oncology units, collects feedback regarding patient satisfaction using smartphones. ... survey tool, because it gives us the timely information ...
(Date:8/21/2014)... August 21, 2014 Entries are now ... the only comprehensive national awards program totally dedicated to ... development and executive leadership. The entry deadline is Oct. ... Real Estate Insights™, the first and only national magazine ... and investment. , “We launched the HREI Insights Awards ...
Breaking Medicine News(10 mins):Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Women's health and Fifty Shades: Increased risks for young adult readers? 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4
... , , MONDAY, March 3 (HealthDay News) -- Parents may not ... a good idea to just have that one big "sex ... you encourage an ongoing dialogue about sex with your children ... kids are less likely to engage in risky sexual behaviors. ...
... Suracell Italy; other ... SOUTH ORANGE, N.J., March 3 Suracell, Inc.,( ... age management programs, announces the launch of the ... its cutting edge programs to,the international audience. DNA ...
... Popovits to be Honored at Gala Dinner in San Francisco ... Calif., Mar. 3 Women,Health Care Executives of Northern California ... of Redwood,City-based Genomic Health, Inc., has been named its 2008 ... dinner to be held at the,Carnelian Room atop the Bank ...
... Access to Local Community, SUNNYVALE, Calif., March ... global leader in the field of radiosurgery,announced today ... second,CyberKnife(R) Robotic Radiosurgery System for its western satellite,location ... will allow those,living in the rural communities easier ...
... Files application to list shares on American Stock ... China Sky One,Medical, Inc. (OTC Bulletin Board: CSKI; ... distributor of pharmaceutical, medicinal and,diagnostic products in China, ... to its board -- including Song Chun Fang, ...
... Uroplasty, Inc. (Amex:,UPI) announced today the ... on,its Urgent(R) PC Neuromodulation System, a proprietary, ... treatment of overactive,bladder (OAB) symptoms, at the ... Symposium in Tampa, Florida. These retrospective and,observational ...
Cached Medicine News:Health News:That 'Sex Talk' With Your Kids Should Be Ongoing 2Health News:That 'Sex Talk' With Your Kids Should Be Ongoing 3Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2Health News:Women Health Care Executives Names Genomic Health President Kimberly Popovits as 'Woman of the Year' 2Health News:St. Louis University Hospital Purchases Second CyberKnife(R) System 2Health News:St. Louis University Hospital Purchases Second CyberKnife(R) System 3Health News:China Sky One Medical, Inc. Appoints Four Independent Board Members 2Health News:China Sky One Medical, Inc. Appoints Four Independent Board Members 3Health News:China Sky One Medical, Inc. Appoints Four Independent Board Members 4Health News:Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium 2Health News:Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: